US biopharmaceutical developer's Q2 net loss narrowed compared to prior yr
Vivani entered non-exclusive agreement with Novo Nordisk to evaluate NPM-139 implant
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
$0.07
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vivani Medical Inc is $4.00, about 192% above its August 12 closing price of $1.37
Result drivers and outlook
Lower expenses - Decreases in R&D and general and administrative expenses contributed to narrower net loss
Vivani anticipates completion of Cortigent-ClearOne merger in Q3 2026
VANI•
